Aditxt, Inc. (ADTX)
After hours:
| Previous close | 1.3800 |
| Open | 1.4300 |
| Bid | 1.3200 x 200 |
| Ask | 1.4100 x 200 |
| Day's range | 1.3100 - 1.4400 |
| 52-week range | 1.3000 - 68.0800 |
| Volume | |
| Avg. volume | 605,496 |
| Market cap | 2.691M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -64.8300 |
| Earnings date | 20 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireEvofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
Live moderated video webcast with Evofem management on Thursday, August 1 at 10:30am ETSAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Women’s health innovator Evofem Biosciences, Inc. (“Evofem” or “the Company”) (OTCQB: EVFM) today announced that Saundra Pelletier, Chief Executive Officer and Amy Raskopf, Chief Business Development Officer, will present and host one-on-one meetings at the OTCQB Venture Virtual Investor Conference as follows: Date:Thursday, August 1, 2024Time:10:30am ETAccess Webca
- Business Wire
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
MOUNTAIN VIEW, Calif., July 25, 2024--Aditxt, Inc. ("Aditxt") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, and its wholly-owned subsidiary, Adivir, Inc., have entered into a second Amending Agreement (the "Amending Agreement") with Appili Therapeutics Inc. ("Appili") (TSX: APLI; OTCPink: APLIF), a biopharmaceutical company developing treatments and vaccines for infectious diseases and medical countermeasures. Under the Amending Agree
PR NewswireEvofem Signs Phexxi® License Agreement for Middle East with Pharma 1
Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM) and private Emirati health care company Pharma 1 Drug Store LLC have signed a License and Supply Agreement for the Middle East rights to Phexxi® (lactic acid, citric acid, potassium bitartrate), Evofem's FDA-approved hormone-free contraceptive.
